FN1 and Duchenne muscular dystrophy: Zanotti et al.33 found that pirfenidone treatment significantly downregulated fibronectin expression in muscle-derived fibroblasts from DMD patients, indicating its potential use in treating fibrosis in dystrophic skeletal muscle.